secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2023-10-03T23:59:59+00:00
Accession:  0001193125-23-249962
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics appoints Dr. Jeffrey W. Sherman to Board of Directors
--------------------------------------------------------------------------

- Board expanded from 5 to 6 members; Dr. Sherman appointed as Class I director through 2024 annual meeting.
- Dr. Sherman is EVP and Chief Medical Officer of Horizon Therapeutics, with extensive biopharma leadership experience.
- Received option to purchase 16,600 shares of common stock, vesting monthly over 36 months.
- Appointed to Nominating and Corporate Governance Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312523249962/0001193125-23-249962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312523249962/d517569d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-249962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer